BioSig Technologies Amends Convertible Debenture Agreement

An update from BioSig Technologies ( (BSGM) ) is now available.

On August 13, 2025, BioSig Technologies amended its secured convertible debenture purchase agreement with YA II PN, LTD. The amendment restructures the transaction to include secured convertible debentures totaling up to $100 million and updates terms such as purchase provisions and conversion floor prices, potentially impacting the company’s financial strategy and stakeholder interests.

The most recent analyst rating on (BSGM) stock is a Buy with a $2.75 price target. To see the full list of analyst forecasts on BioSig Technologies stock, see the BSGM Stock Forecast page.

Spark’s Take on BSGM Stock

According to Spark, TipRanks’ AI Analyst, BSGM is a Underperform.

BioSig Technologies faces significant financial difficulties, with persistent losses, high leverage, and negative cash flow trends. While technical analysis indicates some short-term momentum, potential overbought conditions warrant caution. The negative P/E ratio further underscores valuation challenges and risks associated with the stock.

To see Spark’s full report on BSGM stock, click here.

More about BioSig Technologies

BioSig Technologies, Inc. is a Delaware-based company operating in the medical technology industry, focusing on developing and commercializing advanced signal processing solutions for the healthcare sector.

Average Trading Volume: 1,151,497

Technical Sentiment Signal: Hold

Current Market Cap: $146.3M

For a thorough assessment of BSGM stock, go to TipRanks’ Stock Analysis page.